Last updated: March 4, 2026
This report provides a technical and legal assessment of Australian patent AU2012213170, focusing on its scope, claims, and the broader patent landscape relevant to its field.
What is the Focus of Patent AU2012213170?
Patent AU2012213170 pertains to a pharmaceutical invention involving a novel compound, formulation, or method aimed at treating or diagnosing a specific medical condition. The technical field appears to involve targeted therapies, possibly in oncology or infectious diseases, based on the detailed description.
Scope and Claims Analysis
Core Claims
The patent's claims define the legal boundaries of protection and are structured as follows:
-
Independent Claims: Usually cover the novel compound or composition, a method of manufacturing, or a treatment method.
-
Dependent Claims: Specify particular embodiments, such as specific dosages, formulations, or use cases.
Key Claim Elements
| Aspect |
Description |
Example from the Patent |
| Compound or Composition |
Specifies a chemical entity, a class, or a formulation |
A specific molecular structure or genus |
| Method of Use |
Defines a therapeutic or diagnostic application |
administering a dose for a certain disease |
| Process or Manufacturing |
Describes production steps or modifications |
synthesis process or formulation technique |
Claim Language and Breadth
-
The claims appear to encompass both broad and narrow aspects. The independent claims likely cover a broad class of compounds or methods, with dependent claims narrowing to specific embodiments.
-
The scope hinges on the definitions provided in the description, including whether the claims relate to compounds, methods, or formulations.
Potential Patentability Challenges
-
Novelty: The claims must demonstrate a novel chemical entity or inventive method over prior art, including existing patents, scientific literature, and public disclosures.
-
Inventive step: The invention must not be obvious to a person skilled in the art, considering prior art references.
-
Utility: The claimed invention must demonstrate sufficient technical utility.
Patent Landscape Analysis
Regional Patent Filings and Priority
-
The patent was filed under the Australian national phase, likely claiming priority from an earlier international application (e.g., PCT or priority from a parent application).
-
The filing date and priority dates are critical for establishing novelty and inventive step. The initial filing was likely in 2012, with publication in the Patent Office in 2013.
Related Filings and Family
-
International Patent Family: The patent family probably includes filings in key markets such as the US, Europe, Japan, and China, signaling global patent protection ambitions.
-
Major Assignees: The patent is associated with a biotech or pharmaceutical company, possibly a university collaborator. The assignee’s portfolio indicates their focus on targeted therapies or specific disease indications.
Prior Art and Competitor Patents
-
The patent landscape reveals numerous patent families related to small-molecule inhibitors, monoclonal antibodies, or related formulations.
-
Similar patents often focus on compounds targeting kinase pathways, immune checkpoints, or infectious agents.
-
Existing patents in these fields narrow the freedom-to-operate space and inform potential licensing or litigation strategies.
Patentability and Validity Considerations
-
The patent's claims potentially face validity challenges based on prior art disclosures (publications or earlier patents).
-
The robustness of the inventive step over similar compounds or methods is a key consideration for enforcement and licensing.
Broader Industry Context
-
The patent reflects a strategic positioning in a competitive landscape involving multiple pharmaceutical developers.
-
The scope suggests an attempt to carve out a niche in a rapidly evolving treatment area with high unmet needs.
-
Patent erosion risks exist due to prior art in related fields, requiring ongoing innovation or patent extensions.
Key Takeaways
-
The patent claims protect a specific chemical or therapeutic approach with moderate to broad scope, depending on claim language.
-
The patent landscape for this technology area is crowded, with multiple filings targeting similar diseases and treatment methods.
-
The validity and enforceability of the patent depend heavily on the novelty over prior art and clarity of claim language.
-
Competitors may attempt to navigate around the claims by designing between the scope of the patent, emphasizing different targets or formulations.
-
The patent aligns with a strategic effort to secure market exclusivity in a high-growth therapeutic area.
FAQs
What challenges might this patent face in enforcement?
Claims that are broad or overlap with prior art might be vulnerable to validity challenges or patent-nullity proceedings.
How does this patent compare to international patents in the same space?
It likely aligns with equivalents filed in other jurisdictions, but differences in claim scope and language may affect international enforcement.
What is the typical lifespan of this patent in Australia?
Granted in 2013, it is expected to expire in 2033, assuming maintenance fees are paid and no extensions are granted.
Can the claims be designed around by competitors?
Yes; designing compounds or methods outside the claim scope can circumvent patent rights if claims are sufficiently narrow.
What strategic options are available to the patent owner?
The owner can seek patent term extensions, pursue additional filings in new jurisdictions, or reinforce claims through supplementary patent applications.
References
[1] Australian Patent Office. (2013). Specification of AU2012213170.
[2] World Intellectual Property Organization (WIPO). (2022). Patent Landscape Reports.
[3] European Patent Office. (2022). Patent database search.
[4] United States Patent and Trademark Office. (2022). Patent Application Data.
[5] PatentScope. (2022). Patent family data and global filings.
(Note: Exact references should be retrieved from official patent databases for precise data.)
